ProBioGen, a Berlin-based service & technology provider for complex therapeutic glycoproteins, signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, a privately held immunology company.
Under the terms of the agreement, ProBioGen is developing a stable cell line, followed by process development and GMP clinical manufacturing for Tizona’s lead antibody drug candidate. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.
ProBioGen, founded in 1994, is a privately owned German company specialised in developing and manufacturing complex therapeutic glycoproteins.
Tizona Therapeutics therapies are designed to modulate the activity of immunosuppressive cells by targeting the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment.